Laura Dugo, Marika Collin, and Christoph Thiemermann. Glycogen synthase kinase-3β as a target for the therapy of shock and inflammation. Shock, 27:113-123, 2007.
In the February 2007 issue of Shock we reviewed the role of glycogen synthase kinase-3 beta (GSK-3β) in the pathophysiology of shock and inflammation (1).
We would like to clarify that Table 1 of our review, which summarizes the substrates of GSK-3β, was taken from the excellent review by Jope and Johnson (2). This reference was unintentionally omitted in our published review, and we sincerely apologize for this oversight. The copyright to reproduce this table was granted by Elsevier (3). Figure 1 of our review was loosely based on figures previously published by Cohen and Goedert (4) and Jope and Johnson (2), but modified to suit the purpose of our review. The relevant copyrights to reproduce this modified figure were granted by the respective publishers (3, 5).
1. Dugo L, Collin M, Thiemermann C: Glycogen synthase kinase-3β as a target for the therapy of shock and inflammation. Shock
2. Jope RS, Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Trends Biochem Sci
3. Reprinted from Trends Biochem Sci
, 29, Jope RS and Johnson GV, The glamour and gloom of glycogen synthase kinase-3, pp 95-102. Copyright 2004, with permission from Elsevier.
4. Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov
5. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery. Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov
3:479-487, 2004. Copyright 2004.